For Immediate Release
Chicago, IL – April 2, 2012 – Zacks.com announces the list of
stocks featured in the Analyst Blog. Every day the Zacks Equity
Research analysts discuss the latest news and events impacting
stocks and the financial markets. Stocks recently featured in the
blog include Supervalu Inc.
(SVU), Medco Health Solutions
(MHS), Express Scripts Inc. ( ESRX),
Walgreen Company (WAG) and PACCAR
Inc. ( PCAR).
Get the most recent insight from Zacks Equity Research with the
free Profit from the Pros newsletter:
http://at.zacks.com/?id=5513
Here are highlights from Friday’s Analyst
Blog:
Medco-ESRX Deal Irks Supervalu
The leading grocery chain and heavyweight pharmacy retailer
Supervalu Inc. (SVU) is now an addition to the
list of many pharmacy companies for whom the takeover of
Medco Health Solutions (MHS) by
Express Scripts Inc. ( ESRX) did not go down well.
Supervalu made its view public along with other retail giants
urging the takeover would leave "only two significant competitors
in a highly concentrated industry."
The National Association of Chain Drug Stores (of which
Supervalu is a member), the National Community Pharmacists
Association, and few retail pharmacy companies have filed a lawsuit
at US District Court for the Western District of Pennsylvania
appealing that the merger should be stopped.
Express Scripts wants to takeover Medco Health Solutions for
$29.0 billion. The two pharmacy chains are big players in the field
of Pharmacy Benefit.
Given the large purchasing power, the Pharmacy Benefit Managers
(PBM) negotiate and reduce employers, government agencies and other
clients’ spending on prescription drugs.
If the merger takes place, St. Louis-based Express Scripts and
New Jersey-based Medco would create the largest U.S. PBM,
controlling prescriptions of more than one in three Americans.
Thus, the pharmacy groups are worried that the merger will hurt
several retail pharmacy chains, specialty chains and huge employers
who need pharmacy benefits.
We note, earlier this year that another retail bigwig
Walgreen Company (WAG) had refrained from renewing
its license with Express Scripts.
Therefore, customers who were registered with Express Script had
to refill their prescriptions at new pharmacies or pay for them out
of their own pocket.
Supervalu’s Shop n Save with 50 stores in Illinois and Missouri,
and 34 pharmacies planned to hire more workers and enhance its
pharmacy services to welcome patients with Express Scripts
prescription plans.
It has urged the Express Script customers to transfer
prescriptions well ahead of time, as then the pharmacist at the
Shop n Save stores can arrange for the medicines in advance.
Supervalu holds a Zacks #3 Rank that implies a short term Hold
Rating.
PACCAR Launches New Trucks
With a view to improving its product lines, PACCAR
Inc. ( PCAR) has launched high technology aerodynamic
trucks at the Mid-America Trucking Show in Louisville, Kentucky. It
took nearly 4 years and $400 million to launch these trucks under
the Kenworth T680 and Peterbilt 579 brand names.
The trucks, powered with the company’s own fuel efficient and
high horse-power diesel engines, have a cab width of 2.1 meter.
These trucks form part of the heavy-duty class-8 segment and are
available at low price.
In the fourth quarter of 2011, PACCAR achieved a record Class 8
retail market share of 28.1% in the U.S. and Canada. Class 8
industry retail sales in the U.S. and Canada improved 56% to
197,000 units in 2011 from 126,000 in 2010.
The company reported earnings of 91 cents per share in the
quarter, up from 46 cents per share in the year-ago quarter and the
Zacks Consensus Estimate of 79 cents per share. Net sales and
financial service revenues in the quarter surged 58% to $4.85
billion, which is the highest quarterly revenue in the company’s
history. It also exceeded the Zacks Consensus Estimate of $4.21
billion.
PACCAR expects the truck market to improve in 2012 driven by
recovery in the housing market. With the improvement of the truck
market and introduction of new vehicles, revenues are expected to
reach higher levels in the coming quarters.
Want more from Zacks Equity Research? Subscribe to the free
Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and
qualitative analysis to help investors know what stocks to buy and
which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives
them keen insights to developments that affect company profits and
stock performance. Recommendations and target prices are six-month
time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides
highlights of the latest analysis from Zacks Equity Research.
Subscribe to this free newsletter today:
http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc.,
which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew
he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was
the formation of his proprietary stock picking system; the Zacks
Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations
and market insights of Zacks Investment Research is through our
free daily email newsletter; Profit from the Pros. In short, it's
your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros
at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the
performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an
offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report
MEDCO HLTH SOL (MHS): Free Stock Analysis Report
PACCAR INC (PCAR): Free Stock Analysis Report
SUPERVALU INC (SVU): Free Stock Analysis Report
WALGREEN CO (WAG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Medco (NYSE:MHS)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Medco (NYSE:MHS)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024